Corpus ID: 73456420

Humanistic and economic burden of hepatocellular carcinoma: systematic literature review.

  title={Humanistic and economic burden of hepatocellular carcinoma: systematic literature review.},
  author={Christine G Kohn and Prianka Singh and Beata Korytowsky and Jonathan T. Caranfa and Jeffrey D. Miller and Bruce E Sill and Alexander Marshall and Neehar D. Parikh},
  journal={The American journal of managed care},
  volume={25 2 Spec No.},
OBJECTIVE: Worldwide, more than half a million new cases of hepatocellular carcinoma (HCC) are diagnosed annually. The incidence of HCC in the United States is rising with an estimated 31,000 new cases in 2018. Disease prognosis remains poor, with a 5-year survival rate across all disease stages estimated between 10%-20%, and 3% for those diagnosed with distant disease. Although morbidity is significant, especially among patients with advanced-stage disease, limited information exists on the… Expand
5 Citations
Cost-Effectiveness of Imaging Tumor Response Criteria in Hepatocellular Cancer After Transarterial Chemoembolization.
This study demonstrates qEASL to be the most cost-effective tumor response assessment criterion, with substantial cost savings as compared with RECIST and mRECIST for patients with hepatocellular carcinoma after transarterial chemoembolization. Expand
Optimal multiparametric set-up modelled for best survival outcomes in palliative treatment of liver malignancies: unsupervised machine learning and 3 PM recommendations
Multi-faceted cancer control within the palliative care of liver malignancies is crucial for improved disease outcomes including individualised patient profiling, predictive models and implementation of corresponding cost-effective risks mitigating measures detailed in the paper. Expand
Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma
Follow-up chest CT has limited benefit in the surveillance of HCC patients, especially those with negative baseline chest CT findings, as well as patients with negative CT chest findings at baseline. Expand
Role of tumor margin and ADC change in defining the need for additional treatments after the first TACE in patients with unresectable HCC.
The survival benefit of sequential TACE sessions varies for different HCC subgroups and the most survival benefit was for ADC-nonresponder well-defined group and it was least for ill-defined HCC group, regardless of ADC-response. Expand
Comparison of Drug-Eluting Embolics versus Conventional Transarterial Chemoembolization for the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
PURPOSE To compare the cost-effectiveness of using doxorubicin-loaded drug-eluting embolic (DEE) transarterial chemoembolization versus that of using conventional transarterial chemoembolization forExpand


Population-based risk factors and resource utilization for HCC: US perspective
This claims database analysis suggests a gap exists between screening and treatment guidelines and practice patterns, implying a need for greater health care provider awareness and education. Expand
Hepatocellular Carcinoma: A Decade of Hospitalizations and Financial Burden in the United States
Despite the decrease in mortality rate and length‐of‐stay, hospitalizations and financial burden associated with HCC continued to increase between 2002 and 2011 in the United States. Expand
The burden of illness associated with hepatocellular carcinoma in the United States.
The results exhibit a considerable economic impact of HCC and substantial national spending on this disease, including healthcare costs and the value of lost productivity. Expand
Palliative interventions for hepatocellular carcinoma patients: analysis of the National Cancer Database.
Stratifying by disease stage, palliative RT provided a significant survival benefit for patients with stage IV disease and should be considered for patients presenting with late stage HCC. Expand
Quality of life changes in patients undergoing treatment for hepatocellular carcinoma
There were significant differences in QoL deterioration across different treatment groups and this information may assist patients and providers when selecting patient-centered treatment approaches for HCC. Expand
Sorafenib in Elderly Patients with Advanced Hepatocellular Carcinoma: A Case Series
Sorafenib at a reduced dose can be safely used in elderly HCC patients with maintenance of activity and increased tolerability, and the evaluation of quality of life did not show any significant change during the study. Expand
Role functioning is associated with survival in patients with hepatocellular carcinoma
Role function has prognostic significance and is important to assess in patients with HCC, and was associated with survival on univariate analysis and on survival curves generated using Kaplan–Meier analysis. Expand
Comparative and Cost Effectiveness of Treatment Modalities for Hepatocellular Carcinoma in SEER-Medicare
For patients diagnosed with initial diagnosis of HCC, transplant was most effective in reducing mortality, followed by resection, liver directed, and radiation or chemotherapy, and liver directed therapy was more cost effective than chemotherapy or radiation. Expand
Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study
Mortality due to cirrhosis has been increasing in the US since 2009, driven entirely by alcohol related liver disease, and people aged 25-34 have experienced the greatest relative increase in mortality. Expand
Medical care costs and survival associated with hepatocellular carcinoma among the elderly.
Costs for patients with HCC are approximately 6- to 8-fold higher than for those without this cancer, highlighting that HCC is a substantial medical cost burden for elderly patients. Expand